Andrew J. Oakley was elected to the Board of Directors in 2019 and is regarded as an independent board member.
Special competencies
Andrew is a global executive with more than 30 years of financial and capital markets experience, holding positions as Chief Financial Officer of Actelion, Vectura PLC, Sosei Group Corporation, Autolus Therapeutics PLC and Theolytics Ltd.
Current positions
Andrew currently serves as Chief Financial Officer of TargImmune Therapeutics AG, and is a board member of Novaremed AG, Virometix AG and Onconetix Inc. (ONCO).
Education
Andrew holds a Bachelor of Economics degree from Macquarie University and an MBA from London Business School, United Kingdom. Andrew has been a member of the Australian Institute of Chartered Accountants since 1987.
Nationality
Australian
